A Phase 1, Multicenter, Parallel-Design, Single Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Eloralintide in Participants With Severe Renal Impairment and End Stage Renal Disease (ESRD) Compared With Participants With Normal Renal Function

The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin).
For each participant, the study will last about 14 weeks, excluding screening.

开始日期2026-02-24

申办/合作机构

Eli Lilly & Co.

NCT07369011

/ Recruiting临床3期

A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Moderate to Severe Obstructive Sleep Apnea, and Obesity or Overweight

The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.
Participants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks.

开始日期2026-02-10

申办/合作机构

Eli Lilly & Co.

NCT07392190

/ Recruiting临床3期

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.
Participation in the study will last about 80 weeks.

开始日期2026-02-10

申办/合作机构

Eli Lilly & Co.

100 项与 Eloralintide 相关的临床结果

登录后查看更多信息

100 项与 Eloralintide 相关的转化医学

登录后查看更多信息

100 项与 Eloralintide 相关的专利（医药）

登录后查看更多信息

项与 Eloralintide 相关的文献（医药）

2026-03-01·PEPTIDES

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes

Review

作者: Flatt, Peter R ; Bailey, Clifford J ; Conlon, J Michael

The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limited application as an adjunct to insulin therapy. It acts centrally to induce satiety, promote weight loss, suppress prandial glucagon release and reduce prandial hyperglycaemia. Recent understanding of the heterodimeric structure of amylin-calcitonin receptor complexes and of amylin structure-function properties has assisted the design of a second generation of non-aggregating, long-acting amylin analogues. These are now advancing in clinical development and promise to provide an effective additional resource for the management of obesity and type 2 diabetes. Amongst these agents is the dual AMYR/ calcitonin-receptor (CTR) agonist, cagrilintide that has also been co-formulated into a once weekly subcutaneous injection with the long-acting glucagon-like peptide-1receptor (GLP-1R) agonist, semaglutide (CagriSema). In clinical trials, CagriSema has achieved greater effects than either component alone. A unimolecular AMYR/CTR/GLP-1R multi-agonist peptide, amycretin has been developed for weekly injection and as a once-daily tablet. Several recently developed long-acting amylin analogues have shown strong efficacy as monotherapy in clinical trials: these include eloralintide, petrelintide, Met-233 and AZD6234. Other analogues with marked efficacy in preclinical studies, including non-peptide AMYR agonists are under development. Gastrointestinal side effects, especially nausea, similar to those reported for GLP-1R agonists are commonplace during initiation and up-titration of amylin analogues but mostly resolve during continued use. Evidence is emerging that long-acting AMYR agonists may show potential therapeutic benefits in treatment of patients with fatty liver disease, diabetes-associated kidney complications and resistant hypertension.

2025-12-01·Molecular Metabolism

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept

Article

作者: Tidemann-Miller, Beth ; He, Minxia Michelle ; Tham, Lai San ; Lansu, Katherine ; Pratt, Edward ; Allen, Dawn ; Coskun, Tamer ; Qu, Hongchang ; Long, Annie ; Bowen, Breanna ; Bhattachar, Shobha N ; Mather, Kieren J ; Ibriga, Hilda ; O'Farrell, Libbey ; Moyers, Julie S ; Briere, Daniel A ; Haupt, Axel ; Alsina-Fernandez, Jorge

OBJECTIVES:

Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity.

METHODS:

In vitro assays were performed in cell lines selectively expressing rat or human amylin 1 receptor (AMY1R), amylin 3 receptor (AMY3R), or calcitonin receptor (CTR). In vivo studies were conducted in rats and monkeys. A phase 1, randomized, placebo-controlled, participant/investigator-blinded trial evaluated the safety and tolerability of single-ascending eloralintide doses (0.04-12 mg) in healthy participants (NCT05295940).

RESULTS:

In vitro, eloralintide preferentially activated human AMY1R (12-fold > CTR, 11-fold > AMY3R), while in rats, both AMY1R and AMY3R were activated more potently than CTR. Eloralintide induced significantly less conditioned taste avoidance in lean rats than cagrilintide, a non-selective amylin receptor agonist (p < 0.05). Eloralintide dose dependently reduced food intake and lowered body weight, primarily through fat mass loss, in diet-induced obese rats. Eloralintide demonstrated favorable pharmacokinetics in both rats and monkeys. In the phase 1 trial, 48 healthy participants had a mean body mass index of 27.5 kg/m². Nine participants in the eloralintide cohorts reported 16 adverse events, with most being mild (n = 15/16). Two participants reported 4 gastrointestinal events, including one moderate vomiting event. The pharmacokinetic profile of eloralintide supports once-weekly dosing. In eloralintide cohorts receiving single doses of 4 or 12 mg, week-4 mean percent change from baseline in body weight was -2.5% (p < 0.01) and -4.4% (p < 0.001), respectively, vs placebo (+0.6%).

CONCLUSIONS:

Once-weekly dosing with eloralintide, an AMY1R-selective agonist, may offer a promising new therapeutic with favorable gastrointestinal tolerability for the treatment of obesity.

2025-12-01·LANCET

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

Article

作者: Kazda, Christof ; Mather, Kieren J ; Tidemann-Miller, Beth ; Butler, Annabelle ; Billings, Liana K ; Coskun, Tamer ; O'Hagan, Jessica ; Tham, Lai San ; Hsia, Stanley ; Bays, Harold

BACKGROUND:

Amylin-based therapies are emerging as promising obesity medications. Eloralintide is a novel, selective amylin receptor agonist in development for weight management. We performed a phase 2, double blind, randomised, placebo-controlled trial with the aim of evaluating the efficacy and safety of a range of doses and dose escalation schemes of once-per-week eloralintide versus placebo in adults with obesity or overweight and had at least one weight-related comorbidity.

METHODS:

We enrolled 263 participants from 46 research centres in the USA. Individuals aged 18-75 years with a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related comorbidity and without type 2 diabetes were randomly assigned (2:1:1:1:2:1:2) to receive once-per-week subcutaneous injections of placebo or eloralintide at 1 mg, 3 mg, 6 mg, or 9 mg, or dose escalations of 6-9 mg or 3-9 mg for 48 weeks. The primary endpoint was percent change in bodyweight from baseline after 48 weeks of treatment. Efficacy analyses included all randomly assigned participants, and safety analyses included all participants who were randomly assigned and received at least one dose of study treatment. This study was completed on Aug 14, 2025, and is registered with ClinicalTrials.gov (NCT06230523).

FINDINGS:

Between Feb 5, 2024, and Aug 14, 2025, 263 participants (mean age 49·0 years [SE 12·6], mean bodyweight 109·1 kg [22·8], BMI 39·1 kg/m² [6·8], 204 [78%] female, and 205 [78%] White) were randomly assigned to receive eloralintide (1 mg, n=28; 3 mg, n=24; 6 mg, n=28; 9 mg, n=54; 6-9 mg, n=24; and 3-9 mg, n=52) or placebo (n=53). The efficacy analyses were based on the 263 participants randomly assigned. The mean percent change in bodyweight from baseline after 48 weeks (efficacy estimand) was -9% (1 mg, 95% CI -12·6 to -6·3), -12% (3 mg, -14·9 to -9·8), -18% (6 mg, -20·7 to -14·5), -20% (9 mg, -22·7 to -17·5), -20% (6-9 mg, -22·7 to -17·0), and -16% (3-9 mg, -18·6 to -14·1), compared with -0·4% (-2·2 to 1·4) in the placebo group. The most common adverse events with eloralintide were nausea (1 mg 11%, 3 mg 13%, 6 mg 64%, 9 mg 33%, 6-9 mg 54%, 3-9 mg 25%, and placebo 14%) and fatigue (1 mg 0%, 3 mg 13%, 6 mg 29%, 9 mg 43%, 6-9 mg 46%, 3-9 mg 21%, and placebo 12%).

INTERPRETATION:

Eloralintide produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks and was generally well tolerated, supporting eloralintide's potential use for obesity treatment.

FUNDING:

Eli Lilly.

项与 Eloralintide 相关的新闻（医药）

2026-03-18

·香港证券交易所

自願性公告 - 口服小分子胰淀素受體激動劑ASC39在臨床前模型中顯示出類似eloralintide的胰淀素選擇性與療效

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。自願性公告口服小分子胰淀素受體激動劑ASC39在臨床前模型中顯示出類似eloralintide的胰淀素選擇性與療效在與eloralintide的頭對頭環磷酸腺苷(cAMP)激活實驗中，口服小分子胰淀素受體激動劑ASC39顯示出與eloralintide相似的選擇性與活性。ASC39與 eloralintide對人胰淀素1型受體(hAMY1R)的EC50分別為21.4 pM和21.2 pM。 ASC39與eloralintide對人降鈣素受體(hCTR)的EC50分別為846.1 pM和1,350.8 pM。這些數據表明，相較於hCTR，ASC39與eloralintide都對hAMY1R更具有選擇性，且選擇性相當。在與eloralintide的頭對頭飲食誘導肥胖(DIO)大鼠研究中，ASC39的口服給藥療效與eloralintide的相當，顯示出顯著的、經安慰劑校正後的體重下降， ASC39為6.6%，eloralintide為5.6%。－預計將於2026年第三季度向美國食品藥品監督管理局(FDA)遞交ASC39口服片的新藥臨床試驗申請(IND)。本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。本公司董事（「董事」）會（「董事會」）宣布已選定對胰淀素具有選擇性的強效口服小分子胰淀素受體激動劑ASC39作為臨床開發候選藥物。歌禮預計將於2026年第三季度向美國食品藥品監督管理局(FDA)遞交ASC39口服片治療肥胖症的新藥臨床試驗申請(IND)。 ASC39具有獨特的化學骨架，該化學骨架是利用歌禮基於結構的AI輔助藥物發現（Artificial Intelligence-assisted Structure-Based Drug Discovery，AISBDD）技術自主發現的。在ASC39與eloralintide的頭對頭環磷酸腺苷(cAMP)激活實驗中， ASC39與eloralintide（胰淀素多肽類似物）對人胰淀素1型受體(hAMY1R)的EC50 （半數最大有效濃度）分別為21.4 pM和21.2 pM。ASC39與eloralintide對人降鈣素受體(hCTR)的EC50分別為846.1 pM和1,350.8 pM。這些數據表明，相較於hCTR， ASC39對hAMY1R具有高度選擇性，且ASC39對hAMY1R的選擇性與eloralintide 相當。ASC39與eloralintide對hAMY1R的選擇性比對hCTR的分別高40倍和64倍。在一項頭對頭飲食誘導肥胖(DIO)大鼠研究中，與接受安慰劑給藥的肥胖大鼠相比，ASC39每日口服給藥顯示出具有統計學顯著性的體重下降，與eloralintide相當（見表1）。每日一次口服給藥5 mg/kg的ASC39，連續給藥6天，產生了顯著的經安慰劑校正後的體重下降6.6%。每三天一次皮下注射3 nmol/kg的eloralintide，連續6天，產生了顯著的經安慰劑校正後的體重下降5.6%，與文獻數據一致1。表1. ASC39每日一次口服給藥連續6天產生了具有統計學顯著性的體重下降，其療效與eloralintide的相當。 |組別|給藥|相對基線的總體重變化| |---|---|---| |接受安慰劑給藥的肥胖大鼠|安慰劑，口服，每日一次|0.6%| |接受eloralintide給藥的肥胖大鼠|3 nmol/kg，皮下注射，每三日一次|-5.0% (p<0.0001對比接受安慰劑給藥的肥胖大鼠）| |接受ASC39給藥的肥胖大鼠|5 mg/kg，口服，每日一次|-6.0% (p<0.0001對比接受安慰劑給藥的肥胖大鼠）| 註釋： a. 第1天體重被設為基線。 b. 肥胖大鼠：飲食誘導肥胖大鼠。 ASC39在大鼠與非人靈長類動物中展示了良好的藥代動力學特徵，支持其在人體中每日一次口服給藥。「歌禮致力於為肥胖患者開發治療方案，」歌禮創始人、董事會主席兼首席執行官吳勁梓博士表示，「為此，我們很高興將在今年晚些時候推進首個類似eloralintide 的選擇性胰淀素受體激動劑口服小分子進入臨床。我們相信，ASC39可能提供與禮來(Eli Lilly)的eloralintide相似的療效與安全性，同時具備每日一次口服小分子對患者的便利性，以及商業規模化潛力。」 ASC39是一種對胰淀素具有選擇性的強效口服小分子胰淀素受體激動劑，正在既作為單藥開發，也作為與ASC30聯用（ASC30為歌禮口服小分子、已具備III期條件的GLP-1候選藥物）開發，以治療包括肥胖症在內的代謝性疾病。該新型口服小分子胰淀素項目強化了歌禮現有的胰淀素多肽候選藥物組合，包括ASC36（可每月一次至每季度一次皮下注射的胰淀素多肽單藥療法），以及ASC36與每月一次 ASC35（GLP-1/GIP皮下注射多肽）的固定劑量複方組合。 1 Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025;102:102271. doi:10.1016/ j.molmet .2025.102271 香港聯合交易所有限公司證券上市規則第18A.05條規定的警示聲明：我們無法保證我們將能夠最終令ASC39成功開發、銷售及╱或商業化。於本公告日期，本公司董事會包括執行董事吳勁梓博士及何淨島女士；及獨立非執行董事魏以楨博士、顧炯先生及華林女士。

ASCO会议临床结果临床申请

2026-03-12

·共至咨询

科研最前线｜强生双抗组合获FDA批准，辉瑞ADC管线加速推进！

人才共至智汇未来 www.coarrival.com 01 强生双抗组合获批强生宣布 Tecvayli（teclistamab）联合 Darzalex Faspro 获 FDA 批准，用于既往至少接受过一线治疗的复发或难治性多发性骨髓瘤成人患者。此次批准基于 3 期 MajesTEC-3 研究数据，中位随访 3 年时，联合疗法较标准治疗将疾病进展或死亡风险降低 83%，三年无进展生存率达 83%（对照组仅 30%）。Tecvayli 是全球首款 BCMA/CD3 双特异性 T 细胞衔接器，通过激活 T 细胞精准杀伤肿瘤细胞；Darzalex Faspro 是皮下注射抗 CD38 单抗。联合疗法为多发性骨髓瘤患者提供了全新的二线治疗标准，有望显著改善患者生存预后。这一获批标志着双特异性抗体在血液肿瘤领域的临床价值得到进一步验证，为全球患者带来了更优的治疗选择。 02 辉瑞双抗 ADC 竞速辉瑞将 40% 研发预算投向肿瘤领域，新任肿瘤首席官 Jeff Legos 推动双抗与 ADC 管线快速发展。2025 年辉瑞以 12.5 亿美元首付款拿下 PD-1xVEGF 双抗 PF-08634404 海外权益，目前已启动 7 项临床试验，其中 3 项直接进入 3 期阶段，计划 2026 年 6 月前再添 5 项研究，临床直接对标 K 药。同时辉瑞整合 Seagen ADC 管线，今年上半年将公布靶向整合素 β6 的 ADC sigvotatug vedotin 临床数据，并探索双抗与 ADC 联用治疗膀胱癌。此外辉瑞还计划打通代谢与肿瘤领域研究，探索 GLP-1 等靶点在肿瘤治疗中的应用。辉瑞以速度、广度、创新组合为核心的研发战略，有望在 2028 年迎来关键临床数据读报，重塑肿瘤治疗格局。 03 礼来减重药入中国3期礼来新型长效胰淀素受体激动剂 eloralintide 获中国 CDE 批准，同步开展 3 项全球关键 3 期临床研究，用于体重管理等适应症注册。Eloralintide 每周一次皮下给药，对胰淀素受体具有高选择性，可降低胃肠道反应，2 期研究显示 48 周时最高减重 20.1%，腰围最大降幅 17.1cm，且安全性良好。此次中国加入全球 3 期研究，将加速这款减重创新药在中国的上市进程，为肥胖或超重患者提供更多治疗选择，也体现了中国临床研究在全球新药研发中的重要地位。礼来的布局进一步丰富了中国减重市场的创新疗法，满足患者多样化的临床需求。 04 拜耳管线战略升级拜耳宣布终止一代庞贝病 AAV 基因疗法 ACTUS-101，全力押注二代疗法 AB-1009。AB-1009 采用 AAV8 载体直接靶向肌肉组织（庞贝病病灶核心），搭载密码子优化的 GAA 基因，已获 FDA 快速通道和孤儿药资格，2026 年初启动 1/2 期临床试验。中国企业信念医药为其提供 AAV 衣壳技术及载体生产服务。庞贝病是罕见遗传代谢病，目前尚无根治方法，AB-1009 有望从根源解决遗传缺陷，减少患者对酶替代疗法的依赖。拜耳的管线调整体现了对基因治疗技术迭代的精准判断，为罕见病患者带来新希望，也展现了中外药企在基因治疗领域的深度合作。共至咨询：求职招聘，您的智慧助手！共至咨询携手泰伦仕，服务于海内外近百家生物医药公司。我们把AI技术的应用作为核心战略，标准化数据管理工作，精益化人才服务流程。我们深度探索、百倍投入，最大化赋能人才、顾问和客户。人才共至，智汇未来！ NEWS 感谢关注 NEWS TODAY

2026-03-11

·BioSpace

Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data

Rare disease biotech stocks pop on the news that Vinay Prasad, the FDA’s chief biologics regulator, will depart the FDA at the end of April; Sen. Ron Johnson launches an investigation into recent rare disease drug rejections; and Roche and Zealand’s amylin analog fails to match investor expectations—and Eli Lilly’s rival candidate—in a mid-stage trial. > Listen on Spotify > Listen on Apple Products > Listen on Amazon Music > Listen on iHeart After Friday’s news that Center for Biologics Evaluation & Research Chief Vinay Prasad will leave the FDA—again—at the end of April, stocks for several rare disease drug developers popped. UniQure, in particular, was up 51% in premarket trading on Monday. Prasad in a meeting last Thursday with select journalists called the biotech’s Huntington’s treatment AMT-130 a “failed” therapy, according to STAT News . Shares of Replimune and REGENXBIO —which have suffered rejections during the past year—also rose. One person who is not impressed with the plethora of rare disease drug rejections of late—H.C. Wainwright said in a note Tuesday that there have been at least five cell and gene therapies they believe could have been approved under prior FDA officials—is Wisconsin Senator Ron Johnson . Tuesday, Bloomberg News reported that Johnson has launched an investigation into these recent denials. Johnson called the FDA’s request that uniQure conduct a sham surgery-controlled trial of AMT-130 “bureaucratic idiocy,” according to the publication. Meanwhile, uniQure and the FDA appear to be on different pages regarding the design of this prospective trial, with uniQure Chief Medical Officer Walid Abi-Saab referring to a 10-12 hour surgery during which [burr] holes would be drilled in patients’ skulls and Prasad claiming on a media call last week that it would require only “one to three nicks in the scalp.” In other news, no episode of The Weekly would be complete without our weekly weight loss segment. Roche and Zealand Pharma’s amylin analog fell short of Eli Lilly’s rival candidate eloralintide; AbbVie reported what analysts called “competitive” results, with its amylin analog eliciting nearly 10% weight loss at 13 weeks in a Phase 1 trial; and Regeneron touted a much-needed Phase 3 win for Hansoh-partnered dual GLP-1/GIPR agonist olatorepatide in China. Beyond data, Novo Nordisk and Hims & Hers are together again, with Novo striking a deal to sell its injectable and oral GLP-1 medicines through the telehealth provider. Elsewhere on the business side of biopharma, experts are reporting a cut-throat atmosphere behind doors on the M&A front as the supply of companies available to buy dwindles.

临床1期临床3期临床结果

100 项与 Eloralintide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阻塞性睡眠呼吸暂停综合征	临床3期	美国	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	中国	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	日本	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	阿根廷	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	澳大利亚	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	巴西	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	加拿大	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	德国	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	印度	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	韩国	Eli Lilly & Co.	2026-02-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06230523 (Pubmed \| Lancet)	临床2期	肥胖	263	Eloralintide 1 mg	艱觸鑰齋製廠鑰願糧製(齋範憲膚淵構鑰簾廠遞) = 築餘艱網繭製窪壓築夢構範餘餘糧齋積鬱齋遞 (觸製淵鏇範餘襯襯夢遞, -12.6 ~ -6.3)	积极	2025-12-01
				Eloralintide 3 mg	艱觸鑰齋製廠鑰願糧製(齋範憲膚淵構鑰簾廠遞) = 衊積積鑰繭鹹遞壓淵艱構範餘餘糧齋積鬱齋遞 (觸製淵鏇範餘襯襯夢遞, -14.9 ~ -9.8)
NCT05295940 (Pubmed \| Mol Metab)	临床1期	肥胖	48	Eloralintide	鹽製顧繭窪夢餘餘窪築(遞築鹹醖壓簾鹽鑰齋壓) = 遞壓糧顧鹹繭蓋鬱簾艱醖觸糧鹽襯獵窪鬱淵廠 (選鹹齋製製窪齋衊襯遞 ) 更多	积极	2025-12-01
				Placebo	蓋鑰遞齋餘鏇積製簾餘(艱網築糧選壓鬱醖獵簾) = 淵網選鏇願願衊淵糧構網窪繭壓製繭淵蓋範齋 (鹽獵製憲築夢鹹衊廠齋 ) 更多
NCT06230523 (Company_Website \| Lancet) 人工标引	临床2期	超重 \| 肥胖	263	Eloralintide 1 mg	顧願襯窪鹽顧觸餘積壓(繭憲構襯廠鹽廠壓簾遞) = 醖遞鹹膚築醖膚鏇糧淵製蓋齋網壓積壓醖餘蓋 (鬱鹹構選繭廠廠膚襯鏇 ) 达到	积极	2025-11-06
				Eloralintide 3 mg	顧願襯窪鹽顧觸餘積壓(繭憲構襯廠鹽廠壓簾遞) = 憲衊築範網廠網醖窪衊製蓋齋網壓積壓醖餘蓋 (鬱鹹構選繭廠廠膚襯鏇 ) 达到
NCT06916091 (ADA2025 \| NEWS) 人工标引	临床1期	肥胖	100	Eloralintide dose1	壓鑰觸獵糧壓鹹觸廠餘(醖糧製襯積鹽網鹽簾衊) = 壓鏇艱窪築鏇簾膚廠遞糧膚憲齋遞鬱鬱網繭襯 (衊膚夢鑰夢淵鑰齋構蓋 ) 更多	积极	2025-06-17
				Eloralintide dose2	築廠齋襯膚獵選鏇選選(壓構壓遞齋襯糧醖艱鹹) = 壓蓋簾築膚遞鏇製遞醖繭襯構獵醖築鑰鹹鑰製 (艱構壓艱築廠蓋鬱積鏇 )